Sernova Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Cynthia Pussinen

Chief executive officer

CA$2.6m

Total compensation

CEO salary percentage	3.6%
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.5yrs
Board average tenure	12yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cynthia Pussinen's remuneration changed compared to Sernova's earnings?
Date	Total Compensation	Salary	Company Earnings
Jan 31 2024	n/a	n/a	-CA$41m
Oct 31 2023	CA$3m	CA$92k	-CA$39m

Compensation vs Market: Cynthia's total compensation ($USD1.88M) is above average for companies of similar size in the German market ($USD401.52K).

Compensation vs Earnings: Insufficient data to compare Cynthia's compensation with company performance.

CEO

Cynthia Pussinen

less than a year

Tenure

CA$2,574,600

Compensation

Ms. Cynthia Pussinen is Chief Executive Officer & Director at Sernova Corporation from September 2023. She served as an Executive Vice President of Technical Operations and Supply Chain at Actinium Pharmac...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	no data
Philip Toleikis	President	15yrs	CA$1.21m	1.74% CA$ 1.6m
Modestus Obochi	Chief Business Officer	less than a year	CA$996.01k	no data
Frank Shannon	Vice President of Clinical Development & Regulatory Affairs	2.7yrs	CA$463.26k	no data
Nicholas Rossettos	Interim Chief Financial Officer	less than a year	no data	no data
Douglas Maret	Chief Science Officer	no data	no data	no data
Christopher Barnes	Vice President of Investor Relations	2.3yrs	CA$352.33k	no data

1.5yrs

Average Tenure

Experienced Management: PSH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Cynthia Pussinen	CEO & Director	less than a year	CA$2.57m	no data
Philip Toleikis	President	14.8yrs	CA$1.21m	1.74% CA$ 1.6m
James Parsons	Independent Director	12yrs	CA$183.27k	0.094% CA$ 85.7k
Norman C. Wong	Member of Scientific Advisory Board	17.8yrs	no data	no data
Jannette Dufour	Member of Scientific Advisory Board	17.7yrs	no data	no data
George King	Member of Scientific Advisory Board	no data	no data	no data
Clive Patience	Member of Scientific Advisory Board	17.3yrs	no data	no data
Brett Whalen	Independent Chairman	less than a year	CA$170.23k	0.87% CA$ 797.5k
Steven Paraskevas	Member of Scientific Advisory Board	13.3yrs	no data	no data
David Lillicrap	Member of Scientific Advisory Board	5.3yrs	no data	no data
Anke Schulte	Member of Global Advisory Board	3.8yrs	no data	no data
Sam Wiseman	Member of Scientific Advisory Board	3yrs	no data	no data

12.0yrs

Average Tenure

58yo

Average Age

Experienced Board: PSH's board of directors are seasoned and experienced ( 12 years average tenure).

Sernova Management

Management criteria checks 1/4

Key information

Recent management updates

Sernova Corp., Annual General Meeting, Apr 30, 2024

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Recent updates

New major risk - Share price stability

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

Chairman recently bought €162k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought €51k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

New 90-day high: €0.61

New 90-day high: €0.41

New 90-day high: €0.25

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

New 90-day high: €0.23

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age